<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02599922</url>
  </required_header>
  <id_info>
    <org_study_id>AGTC_CNGB3-001</org_study_id>
    <secondary_id>R24EY022023</secondary_id>
    <nct_id>NCT02599922</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia</brief_title>
  <official_title>A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Applied Genetic Technologies Corp</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Applied Genetic Technologies Corp</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of&#xD;
      AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia&#xD;
      caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the&#xD;
      secondary study endpoint will be efficacy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a non-randomized, open-label, Phase 1/2 study of the safety and efficacy of&#xD;
      AGTC-401 administered to one eye by subretinal injection in individuals with achromatopsia&#xD;
      caused by mutations in the CNGB3 gene. The primary study endpoint will be safety and the&#xD;
      secondary study endpoint will be efficacy.&#xD;
&#xD;
      Subjects will be enrolled sequentially in seven dosing groups. Subjects in Groups 1, 2, 3, 4,&#xD;
      5, and 6 will be at least 18 years of age and will receive varying dose levels of study&#xD;
      agent. Subjects in Group 4a will be 6 to 17 years of age and will receive the same dose as&#xD;
      Group 4. Subjects in Groups 5a and 7 will be between 4 and 8 years of age. Subjects in Group&#xD;
      5a will receive the same dose as Group 5, and subjects in Group 7 will receive the maximum&#xD;
      tolerated dose identified in Groups 1, 2, 3, 4, 4a, 5, 5a, and 6.&#xD;
&#xD;
      Safety will be monitored by evaluation of ocular and non-ocular adverse events and hematology&#xD;
      and clinical chemistry parameters. Efficacy parameters will include visual acuity, light&#xD;
      discomfort testing, color vision, static visual field, ERG, adaptive optics retinal imaging,&#xD;
      functional MRI (fMRI), color brightness test and OCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants experiencing grade 3 or greater adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in best corrected visual acuity compared to pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Light aversion</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in light discomfort testing compared to pre-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <time_frame>1 year</time_frame>
    <description>Changes in color vision testing compared to pre-treatment</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Achromatopsia</condition>
  <arm_group>
    <arm_group_label>Group 1: 2.0 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with 2.0 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: 4.0 x 10^10 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with 4.0 x 10^10 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: 1.2 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with 1.2 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: 3.6 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4a: 3.6 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 6 to 17 y/o treated with 3.6 x 10^11 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: 1.1 x 10^12 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5a: 1.1 x 10^12 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 4 to 8 y/o treated with 1.1 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6: 3.2 x 10^12 vg/mL of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects at least 18 y/o treated with 3.2 x 10^12 vg/mL of rAAV2tYF-PR1/7-hCNGB3 study drug.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7: MTD of AGTC-401</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 4 to 8 y/o treated with a maximum tolerated dose of rAAV2tYF-PR1/7-hCNGB3 study drug determined by Groups 1-6.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rAAV2tYF-PR1.7-hCNGB3</intervention_name>
    <description>rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.</description>
    <arm_group_label>Group 1: 2.0 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 2: 4.0 x 10^10 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 3: 1.2 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 4: 3.6 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 4a: 3.6 x 10^11 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 5: 1.1 x 10^12 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 5a: 1.1 x 10^12 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 6: 3.2 x 10^12 vg/mL of AGTC-401</arm_group_label>
    <arm_group_label>Group 7: MTD of AGTC-401</arm_group_label>
    <other_name>AGTC-401</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria include:&#xD;
&#xD;
          1. Male or female subjects with documented mutations in both alleles of the CNGB3 gene;&#xD;
&#xD;
          2. Retinal disease consistent with a clinical diagnosis of achromatopsia;&#xD;
&#xD;
          3. At least 18 years of age for Groups 1, 2, 3, 4, 5 and 6. At least 6 years of age for&#xD;
             Group 4a, and 4-8 years of age for Groups 5a and 7;&#xD;
&#xD;
          4. Able to perform tests of visual and retinal function;&#xD;
&#xD;
          5. Visual acuity in the study eye not better than 55 ETDRS letters (Snellen equivalent&#xD;
             20/80) based on the average of two examinations at the baseline visit;&#xD;
&#xD;
          6. Acceptable laboratory parameters;&#xD;
&#xD;
          7. For females of childbearing potential: A negative pregnancy test within 2 days before&#xD;
             administration of study agent.&#xD;
&#xD;
        Exclusion Criteria include:&#xD;
&#xD;
          1. Best-corrected visual acuity difference between the two eyes of &gt; 15 ETDRS letters (3&#xD;
             lines);&#xD;
&#xD;
          2. Evidence of degenerative myopia in the study eye;&#xD;
&#xD;
          3. Pre-existing eye conditions that would contribute to vision loss in either eye or&#xD;
             increase the risk of subretinal injection in the study eye.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Feinsod, MD</last_name>
    <role>Study Director</role>
    <affiliation>Applied Genetics Technologies Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill Dolgin, PharmD</last_name>
    <phone>833-770-2862</phone>
    <email>advocacy@agtc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>VitreoRetinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bascom Palmer Eye Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pangere Center for Inherited Retinal Diseases, The Chicago Lighthouse for People Who Are Blind or Visually Imp</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear Infirmary</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia College of Physicians and Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Duke Eye Center, Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cincinnati Eye Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Cole Eye Institute</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Casey Eye Institute, Oregon Health and Sciences University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin, McPherson Eye Research Institute</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hadassah-Hebrew University Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.agtc.com</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Kom√°romy AM, Alexander JJ, Rowlan JS, Garcia MM, Chiodo VA, Kaya A, Tanaka JC, Acland GM, Hauswirth WW, Aguirre GD. Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet. 2010 Jul 1;19(13):2581-93. doi: 10.1093/hmg/ddq136. Epub 2010 Apr 8. Erratum in: Hum Mol Genet. 2011 Dec 15;20(24):5024.</citation>
    <PMID>20378608</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 5, 2015</study_first_submitted>
  <study_first_submitted_qc>November 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2015</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Color Vision Defects</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

